|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040214872A1
(en)
|
2002-09-26 |
2004-10-28 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
EP1740615B1
(en)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DK2339014T3
(en)
|
2005-11-16 |
2015-07-20 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
|
WO2007070659A2
(en)
|
2005-12-14 |
2007-06-21 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CN105085313A
(zh)
|
2005-12-30 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
|
AU2007215566A1
(en)
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
|
CN101578264A
(zh)
|
2006-12-18 |
2009-11-11 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
|
US20100098630A1
(en)
|
2006-12-28 |
2010-04-22 |
Ambrx, Inc. |
Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
JP5620106B2
(ja)
*
|
2007-10-24 |
2014-11-05 |
株式会社糖鎖工学研究所 |
増強されたエフェクター機能を有するポリペプチド
|
|
HRP20150279T1
(hr)
*
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
KR20160070165A
(ko)
|
2008-02-08 |
2016-06-17 |
메디뮨 엘엘씨 |
Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
|
|
AU2009296267B2
(en)
|
2008-09-26 |
2013-10-31 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
|
EP2711018A1
(en)
*
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
JP6152090B2
(ja)
|
2011-04-21 |
2017-06-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
視神経脊髄炎を処置するための組成物および方法
|
|
KR102356286B1
(ko)
|
2011-05-27 |
2022-02-08 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
|
|
CN110078789A
(zh)
|
2011-05-27 |
2019-08-02 |
Ambrx 公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
|
HK1200322A1
(en)
*
|
2011-10-24 |
2015-08-07 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
|
KR102332303B1
(ko)
*
|
2013-05-31 |
2021-11-26 |
자임워크스 인코포레이티드 |
감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
|
|
MX384984B
(es)
*
|
2013-10-10 |
2025-03-14 |
Beth Israel Deaconess Medical Ct Inc |
Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
|
|
EP3071561B1
(en)
|
2013-11-22 |
2021-03-24 |
Sabre Therapeutics LLC |
Autotaxin inhibitor compounds
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
EP3268047B9
(en)
*
|
2015-03-09 |
2024-01-10 |
Heidelberg Pharma Research GmbH |
Amatoxin-antibody conjugates
|
|
TWI812873B
(zh)
*
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR20180105227A
(ko)
*
|
2016-02-02 |
2018-09-27 |
메디토페 바이오사이언시스, 아이엔씨. |
항-egfr 항체 약물 접합체
|
|
MX2020002241A
(es)
|
2017-08-28 |
2020-09-03 |
Angiex Inc |
Anticuerpos anti-tm4sf y métodos de uso de los mismos.
|
|
EP3807644A4
(en)
|
2018-06-12 |
2022-07-06 |
Angiex, Inc. |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
|
|
EP4126042A2
(en)
|
2020-03-27 |
2023-02-08 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
|
WO2021222783A1
(en)
|
2020-05-01 |
2021-11-04 |
Angiex, Inc. |
Anti-tm4sf1 antibody drug conjugates and methods of using same
|
|
EP4188449A4
(en)
|
2020-07-31 |
2025-12-17 |
Angiex Inc |
ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH
|
|
WO2022046941A1
(en)
|
2020-08-26 |
2022-03-03 |
Angiex, Inc. |
Antimitotic tetrapeptide-antibody conjugates and methods of using same
|